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maceutical company is called upon to present 
in-depth documentation for the new drug on 
all relevant aspects, among which economic 
evaluation.
Direct costs
The economic costs of disease can be divi-
ded into direct, indirect, and intangible costs 
[2]. From a societal perspective, direct costs 
are the value of resources used to prevent, 
detect, and treat a health impairment or its 
effects [3]. These costs encompass both he-
althcare and non-healthcare costs: the former 
are defined as the medical expenditures for 
diagnosis, treatment, and rehabilitation, etc.; 
while the latter, borne by the patient and his/
her family, are related to the consumption of 
non-healthcare resources like transportation, 
household expenditures, relocating, property 
losses, and informal cares of any kinds [4].
IntroductIon
Italian background
In Italy, pharmaceutical companies have 
been required to provide economic evalua-
tions when applying for pricing and reim-
bursement negotiations since 1997 [1]. As 
occurs in most European Union countries, 
almost all recently commercialized drugs in 
Italy come from the Centralized Approval 
Procedure, where the European Medicines 
Agency (EMA) must decide if a product con-
stitutes a significant innovation in order to be 
evaluated. In a health care system such as the 
Italian one, based on a National Health Ser-
vice that provides most drugs free of charge 
to its citizens, pricing negotiations with the 
regulatory authorities take place when the 
product is filed for reimbursement. The phar-
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AbstrAct
We developed a general model for estimating and comparing disease- and treatment-specific lost paid/unpaid production 
(due to premature death and reduced ability) and informal care received (due to reduced ability) in Italy, starting from sur-
vival, demographic and Health-Related Quality of Life (HRQoL) data. Assuming the disease is not selecting a systemati-
cally different population in terms of mean wage than the general public, age- and gender-specific yearly production values 
are estimated combining data from the last Italian Time-Use-Survey on time dedicated to paid and unpaid (household, 
caring and volunteering) activities, with a) the last Italian Wage-Structure-Survey, for paid activities (Human Capital ap-
proach), and b) market prices for an equivalent service, for unpaid production (Proxy Good approach). To avoid double 
counting, age- and gender-specific maximum care needs are approximated with time dedicated to eating and personal care, 
reported in TUS. Present monetary values of future productivity and informal care are estimated applying a 3.5% annual 
discount rate. Lost life years due to a particular condition/treatment are estimated by comparison of its survival curve with 
the corresponding age- and gender-normalized survival curve of the general Italian population. The degrees of reduced pro-
ductivity and need for informal care for remaining life years are estimated by comparison of condition-/treatment-specific 
reported HRQoL data with demographically matched Italian norms. Our results will be useful for cost-effectiveness and 
budget impact analyses conducted from the perspective of the Italian society and we encourage the inclusion of these costs 
in economic evaluations to allow decision makers to be fully informed about the costs and consequences of their decisions 
on healthcare interventions.
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Since indirect costs do not directly influence 
expenditures for treating the underlying dise-
ase, they are not easily measurable. However, 
indirect costs often strongly influence the re-
sult of economic evaluations of health care 
programs as shown in Krol et al. [12].
Intangible costs
Intangible costs relate to the non-monetary 
consequences that are by definition difficult 
to measure and assess, such as pain and suffe-
ring associated with the disease. Even though 
these would be duly quantified, they should 
not be included. Being intangible, costs re-
presented by psychological and physical 
discomfort associated with the state of the 
disease, they are usually already adequately 
measured in effectiveness, for example, by 
faster healing or decreased side-effects, as 
well as by greater quality of life (utility) as-
sociated with the condition [15].
The number of economic evaluations of 
pharmaceuticals is rapidly growing, and so is 
their relevance. In Italy, pharmacoeconomics 
has gained importance since the National 
Drug Committee (Commissione Unica del 
Farmaco) listed this as one of the subjects 
to be considered in submitting approval dos-
siers for innovative drugs [16]. Indirect costs 
and informal care are a considerable part of 
the economic burden of diseases and should 
therefore be carefully taken into account.
The Italian guidelines for economic evalua-
tions [4] stress that, in the evaluation carried 
out from society’s point of view, the cost esti-
mates must consider both direct costs (medi-
cal and non-medical) and indirect costs. Ho-
wever, in Italy, until a few years ago, studies 
evaluating indirect costs were only few [17].
With this in mind, we developed a standar-
dized method for estimating and comparing 
condition- and treatment-specific lost paid 
and unpaid production (due to premature 
death and reduced ability) and informal care 
received (due to reduced ability to cope with 
every day’s tasks), in Italy, starting from sur-
vival, demographic and health-related quality 
of life (HRQoL) data. 
Methods
estimating indirect costs
Productivity losses may occur both in paid 
and in unpaid work, due to either premature 
death or reduced ability, or both. According 
to Capri et al. [15], for the estimation of paid 
productivity losses the Human Capital appro-
ach [18] should be used.
Human Capital approach assumes that the 
value to society of productivity losses should 
Informal care
Informal care constitutes a substantial part of 
the total care received by (especially chroni-
cally ill) patients and elderly in many countri-
es [5,6]. Informal care can complement and 
substitute the formal care patients receive. It 
can complement formal care, for example, 
when informal caregivers assist patients with 
the management of their disease or medi-
cation. This improves the overall quality of 
care for patients who are not fully indepen-
dent (e.g., in the context of aging, dementia, 
mental illness) [7,8]. Informal care can also 
substitute formal care by supporting patients 
to stay at home longer or to be discharged 
from formal care sooner [9-11].
When performing an economic evaluation 
in health care, ignoring informal care is pro-
blematic, because it may result in biased cal-
culations of cost effectiveness and, hence, in 
wrong policy information and decisions. In 
Krol et al. [12], for instance, the large impact 
that ignoring productivity costs can have on 
the outcomes of evaluations is highlighted: in-
cluding them changes the main conclusion on 
the cost-effectiveness of the technology being 
considered. Ignoring the costs and effects of 
informal care may have similar impacts, espe-
cially in the context of disease areas where in-
formal care is relatively important, such as in 
the case of Alzheimer’s disease or rheumatoid 
arthritis. For a thorough discussion on this 
subject refer to van den Berg et al. [13].
An informal caregiver can be defined as a 
person who provides care and support to a 
family member, friend, or acquaintance with 
a chronic illness, disability, or other long-la-
sting care need due to ill health or aging [14]. 
Two main types of costs of informal care can 
be distinguished:
1. Out-of-pocket expenses, such as travel 
expenses;
2. Time dedicated to caring (the major com-
ponent).
In general, informal care activities can be di-
stinguished in three categories:
1. Household work: such as cleaning, coo-
king, groceries shopping and other chores 
around the house;
2. Personal care: such as dressing, washing, 
combing, feeding, and medicating;
3. Practical support: such as moving outside 
the house, going to the physician and ta-
king care of daily duties (e.g. going to the 
post office).
Indirect costs
Indirect costs comprise the value of produc-
tion lost to society due to absence from work, 
reduced ability, and death of productive pe-
ople, for both paid and unpaid activities [3]. 
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1. Household work: such as cleaning, coo-
king, groceries shopping and other chores 
around the house;
2. Caring, for family members and for 
others: such as taking care of (grand)
children, helping out friends or family 
with cleaning, shopping or personal care;
3. Volunteer work: such as helping out in a 
community center or at a sports club.
In order to give a monetary value to both 
household production and caring production, 
the model uses the minimum wage for a do-
be measured as the present value of futu-
re lost time, valued according to the market 
gross wage. Therefore, all the working hours 
lost because of health impairment and related 
treatments are valued according to the indivi-
dual gross income.
Unpaid work is the production of goods and 
services that are not sold on a conventional 
market [19]. In Capri et al. [15] it is sugge-
sted to use the Proxy Good approach to esti-
mate unpaid productivity losses. With this 
approach, the monetary value of unpaid work 
is based on the value of the closest market 
substitute. Housework, for instance, can be 
valued using the average price of a professio-
nal housekeeper.
Societal cost of premature death
The last available Italian Time Use Survey 
– TUS – [20] provides data on how people 
arrange their daily routine (Table I). Based 
on these data, the model estimates age- and 
gender-specific yearly time dedicated to both 
paid and unpaid activities. These data have 
been supplemented with Italian age- and gen-
der-specific life expectancies [21].
In order to give a monetary value to paid 
work, data were taken from the last available 
Italian Wage Structure Survey [22], provi-
ding information on the relationships betwe-
en the level of remuneration and individual 
characteristics of employees (sex, age, occu-
pation, length of service, highest educational 
level attained, etc.) and those of their emplo-
yer. In particular, it reports gender-specific 
average hourly gross wage per age-class (Ta-
ble II).
Under the assumption that the disease is not 
selecting a systematically different popula-
tion in terms of mean wage than the general 
public, our model estimates age- and gender-
specific yearly paid production value by 
combining the above data (Table III).
For what concerns unpaid production, we di-
stinguish three main types of activities:
time use in daily activity (h.min)
Gender Male Female
Age 3-5 6-10 11-14 15-24 25-44 45-64 65+ 3-5 6-10 11-14 15-24 25-44 45-64 65+
Eating 2.00 2.00 2.00 1.53 1.57 1.58 2.11 2.00 2.00 2.00 1.52 1.51 1.54 2.00
Caring for oneself 1.00 1.00 1.00 0.53 0.53 0.54 1.00 1.00 1.00 1.00 1.04 0.53 0.52 0.55
Paid work - - - 1.49 5.47 4.24 0.21 - - - 1.06 2.59 2.00 0.04
Household activities 0.13 0.15 0.19 0.17 0.39 1.19 1.53 0.11 0.26 0.38 1.06 3.20 4.42 4.31
Caring for family 
members
- - - 0.02 0.22 0.08 0.05 - - - 0.09 1.01 0.12 0.04
Caring for others - - - 0.01 0.03 0.06 0.10 - - - 0.03 0.05 0.14 0.11
Volunteering - - - 0.01 0.01 0.03 0.02 - - - 0.03 0.01 0.02 0.03
table I. Daily activities of interest from TUS [20]
Age-class (years)
hourly gross wage (€/h)
Male Female
14-19 9.75 9.38
20-29 11.37 10.88
30-39 14.49 13.61
40-49 17.29 15.77
50-59 19.98 18.21
60+ 24.80 20.85
table II. Gender-specific average hourly gross wage per age-class
Age-class (years)
Paid production value (€/years)
Male Female
3-14 - -
15-19 6,465 3,766
20-24 7,539 4,368
25-29 24,001 11,847
30-39 30,587 14,820
40-44 36,498 17,172
45-49 27,768 11,512
50-59 32,088 13,293
60-64 39,829 15,221
65+ 3,168 507
table III. Estimated age- and gender-specific yearly paid production value
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refore the need of additional informal care) 
and of the reduced productivity.
Therefore, the model needs condition/
treatment-specific HRQoL data in order to 
estimate the Societal cost of reduced ability. 
Given the difference between the “degree of 
capability” – as measured, for instance, by 
the physical functioning and role functioning 
scales of the EORTC QLQ-C30 questionnai-
re – of the population under study and the Ita-
lian norms – i.e. the disease-/treatment-spe-
cific ability impairment, the model estimates 
age- and gender-specific values of lost pro-
duction for both paid and unpaid activities.
In order to clarify how the observation of a 
reduced score on HRQoL is translated to a 
societal cost of reduced ability suppose that 
the Italian health norm index for the domain 
“usual activities” is 80 while that of a popu-
lation under treatment is 64. Then, the model 
assumes that the disease under study brings 
about a health impairment of 20% (computed 
as the relative reduction in the health norm 
index ). What is important at this stage is that 
the two health norms are measured on the 
same scale.
Afterwards, the model assumes that this im-
pairment has the same impact on all the daily 
activities. Consider paid activities: if on ave-
rage a person spends 5 hours a day working, 
a person of the population under study will 
be able to spend just 4 hours a day working, 
because of his health impairment. This means 
that these people would be able to produce 
20% less of the yearly value of paid produc-
tion. Same holds true for unpaid activities.
This example is simplistic (in the model there 
are age- and gender- specific values) but the 
idea is that the value of the health impairment 
is a good proxy to determine the values of 
lost production, both paid and unpaid, and 
therefore to determine the burden the Society 
has to bear because of the health impairment.
Many validated measurements instruments, 
to collect data about health-related produc-
tivity loss, ask respondents to provide infor-
mation about their productivity during a pre-
ceding period, but this can be cumbersome. 
Our aim here is to provide a practical method 
that needs the typical data available from cli-
nical studies (e.g. age, sex, survival data and 
health-related quality of life).
estimating informal care
If both costs related to unpaid work and the 
costs related to informal care are included 
one needs to be aware of potential double 
counting [19]. In order to avoid incurring this 
error, since the model already estimates the 
value of lost unpaid production due to redu-
ced ability, informal care costs only account 
mestic worker of level C-Super1 (€ 8.21), as 
defined within the National Collective Bar-
gaining Agreement for Domestic Workers 
[23].
On the other hand, to estimate the monetary 
value of volunteering, the hourly gross wage 
(€ 11.33) has been computed based on the 
median annual gross wage, weekly hours and 
working weeks as reported in [24].
With these data, the model estimates age- and 
gender-specific value of yearly unpaid pro-
duction (Table IV).
Societal cost of reduced ability
Age- and gender-specific health benchmark 
are derived from Szende et al. [25], repor-
ting self-reported population norms for 24 
countries, based on the EQ-5D2 questionnai-
re [26]. Given this, the model assumes that 
every year of life lived “below the norm” de-
termines Societal costs, in terms of both paid 
and unpaid reduced production and in terms 
of augmented need of informal care.
In particular, rather than considering the glo-
bal index value of EQ-5D, the model consi-
ders the following two domains:
1. Self-care: asking about the ability to wash 
or dress by oneself;
2. Usual activities: asking about the ability 
to perform daily activities (e.g. work, stu-
dy, leisure activities).
Then the model estimates the health impai-
rment as domain-specific percentage reduc-
tions. The underlying assumption is that the-
se reductions are a good proxy, respectively, 
of the reduced ability to care for oneself (the-
1 Belong to this category domestic workers, possessing 
specific basic knowledge, both theoretical and technical, 
related to completing the assigned tasks, able to work with 
autonomy and responsibility
2 The EQ-5D is a generic preference-based measure where 
health status is divided into five dimensions (mobility, 
self-care, usual activities, pain / discomfort and anxiety 
/ depression). It was developed by the EuroQol Group in 
order to provide a simple, generic measure of health for 
clinical and economic appraisal
Age-class (years)
Unpaid production value – household, caring, 
and volunteering activities (€/years)
Male Female
3-5 649 549
6-10 749 1,299
11-14 949 1,898
15-24 1,068 4,102
25-44 3,265 13,354
45-64 4,852 15,521
65+ 6,531 14,491
table IV. Estimated age- and gender-specific yearly unpaid production value 
(household activities, caring activities and volunteering)
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results
Premature death: productivity loss
On the basis of the estimated yearly paid and 
unpaid production values (respectively Ta-
ble III and Table IV) and life expectancies, 
the model estimates age- and gender-specific 
present value of future productivity (both 
paid and unpaid), applying a 3,5% yearly 
discount rate. This represents the burden the 
society has to bear for premature death.
As shown in Figure 1, the overall present 
value of future productivity (both paid and 
unpaid) increases with age up to 25, then 
decreases more rapidly for men, with values 
crossing at age 58.
The model estimates lost life years due to a 
particular condition/treatment by comparing 
its survival curve with the corresponding 
age- and gender-normalized survival curve 
of the general Italian population [21]. Figure 
2 shows an example of this comparison.
For estimating condition-/treatment-specific 
societal cost of premature death, the model 
takes into account the “natural mortality” of 
Figure 1. Estimated present value of future productivity (both paid and unpaid)
for the time dedicated by the caregivers to the 
assistance in feeding and personal care.
To make thing clearer consider the following 
example. The last available Italian TUS also 
reports age- and gender-specific daily time 
spent for eating and personal care (Table I). 
Thus, if a 63-years-old male spends, on ave-
rage, 172 minutes a day for eating and perso-
nal care, the model assumes that a 63-years-
old male with reduced ability cannot receive 
more than 172 minutes a day of informal care. 
Obviously, the time of informal care needed 
depends on the level of reduced ability: the 
bigger the health impairment, the more the 
informal care needed.
In this sense, the estimated average yearly 
time dedicated to eating and personal care is 
an upper bound for the hours of informal care 
a person may need.
In order to give a monetary value to informal 
care, following the Proxy Good approach, the 
model uses the minimum wage for a dome-
stic worker of level D-Super3 (€ 9.77), as de-
fined within National Collective Bargaining 
Agreement for Domestic Workers [23].
The model then estimates age- and gender-
specific yearly maximum value of informal 
care one may need (Table V).
Informal care is a cost the society has to bear 
when someone has a reduced ability. There-
fore, the model needs condition/treatment-
specific health-related quality of life data in 
order to estimate the societal cost of informal 
care, as shown above for lost production.
3 Belong to this category domestic workers that, possessing 
the necessary professional qualifications, cover specific job 
positions with responsibilities, decision-making autonomy 
and / or coordination
Maximum value of informal care needed (€/year)
Age-class (years) Male Female
3-14 10,698 10,698
15-24 9,866 10,460
25-44 10,104 9,928
45-64 10,223 10,043
65+ 11,352 10,410
table V. Estimated age- and gender-specific yearly maximum value of informal 
care needed
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was measured using the EORTC QLQ-C30 
[28], a validated instrument in this patient po-
pulation [29-31] that has been widely used in 
clinical trials of multiple myeloma.
The EORTC QLQ-C30 is a disease specific 
questionnaire developed specifically for use 
in cancer. There are 5 functional scales physi-
cal, role, emotional, cognitive and social, a 
global health item, 3 symptom scales –fati-
gue, nausea/vomiting and pain, and single 
symptom items – dyspnea, appetite loss, con-
stipation, diarrhea, and financial difficulties. 
All items are converted onto a 0 to 100 scale. 
With a total of 30 questions the instrument 
gives a broad and sensitive assessment of 
HRQoL in patients with cancer.
In order to compare the results of this que-
stionnaire with the Italian data reported 
in Szende et al. [25], rather than mapping 
QLQ-C30 results onto EQ-5D to derive a 
single utility index, the model applies the 
scoring algorithm developed for QLQ-C30 
[32] to EQ-5D raw numbers. In particular, 
we were interested in comparing “self-care” 
and “usual activities” domains of EQ-5D 
(Table VI), respectively, with “physical fun-
ctioning” and “role functioning” subscales 
of QLQ-C30 of ASPIRE trial, as reported in 
Aaronson et al. [28].
In particular, from the trial emerged that 
even if point estimates tended to favor KRd, 
no statistically significant differences were 
observed between the KRd and Rd groups 
for the “physical functioning” and “role 
functioning” subscales. Similarly, for what 
concerns these subscales, changes from ba-
seline within treatment groups were neither 
Age-class 
(years)
“self-care” domain “Usual activities” domain
Male Female Male Female
3-24 99.75 99.55 98.76 98.88
25-34 99.45 99.44 98.35 98.55
35-44 99.79 99.90 99.05 98.65
45-54 99.65 98.52 97.70 95.11
55-64 97.44 97.66 94.60 92.15
65-74 97.80 93.93 91.94 86.64
75+ 92.48 85.22 80.83 71.51
table VI. Estimates of age- and gender-specific Italian population norms for what 
concerns “self-care” and “usual activities” domains
Italian population. Thus, the cost of prema-
ture death has to be interpreted as the incre-
mental burden for society due to premature 
death for the specific condition/treatment.
Reduced ability: productivity 
loss and informal care
The model estimates age- and gender-spe-
cific yearly values of lost productivity and 
need for informal care due to reduced ability 
by comparing condition-/treatment-specific 
HRQoL data with demographically matched 
Italian norms.
In order to make things clearer, consider the 
following application of the methodology de-
veloped.
In the ASPIRE trial [27], a randomized, 
open-label, phase 3 trial, which evaluated 
the efficacy and safety of carfilzomib with 
lenalidomide and dexamethasone (KRd) ver-
sus lenalidomide and dexamethasone (Rd) in 
relapsed multiple myeloma patients, HLQoL 
Figure 2. Example of comparison of two condition/treatment-specific survival curves (KRd and Rd in relapsed multiple myeloma patients) 
with the Italian population survival curve
Ita = Italian population; KRd = carfilzomib with lenalidomide and dexamethasone; Rd = lenalidomide and dexamethasone
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We made an effort to come up with a com-
prehensive methodology. However, some li-
mitations need to be observed. Our aim was 
to offer guidance and a practical method to 
estimate productivity costs and informal care 
for inclusion in economic evaluations, given 
the typical data availability from clinical stu-
dies.
Still, some assumptions may be considered 
too simplistic, such as applying average age- 
and gender-specific wage rates for the valua-
tion of lost paid production. This, however, 
can be accounted for assessing the impact of 
diseases known to affect a particular social 
stratum; however, one needs to carefully as-
sess the ethical implications of such a choice.
As said, the model values lost paid produc-
tion according to Human Capital approach. 
Yet, the valuation of health-related produc-
tivity changes in economic evaluations is 
extensively debated in the scientific literature 
[19]. An alternative approach to the Human 
Capital is the so-called Friction Cost appro-
ach [36,37]. This is based on the assumption 
that, given involuntary unemployment, an 
ill individual can eventually be replaced by 
a healthy worker. Hence, initial productivity 
levels can be restored after a “friction pe-
riod”.
Both because this approach is less 
straightforward to apply – it requires further 
assumptions and estimates of the length of 
the friction period – and because Human Ca-
pital is suggested in Capri et al. [15], the mo-
del estimates lost paid production according 
to this last approach.
In addition, the absence of a validated me-
asurement instrument – such as the Health 
and Labor Questionnaire (HLQ) or the iMTA 
Productivity Cost Questionnaire (iPCQ) or 
the Valuation of Lost Productivity (VOLP) – 
to collect data regarding both paid and unpaid 
production and informal care can be seen as 
a limitation. In fact, we are not claiming that 
the model may substitute well conducted em-
pirical research, but we offer the possibility 
to obtain a well-informed and balanced esti-
mate of such costs, starting from data that are 
generally available to researchers.
statistically nor clinically significant – with 
the exception of Rd at cycle 12 in physical 
functioning.
Given this, instead of defining treatment – 
and subscale-specific levels of activity, we 
weighted all the “physical functioning” and 
“role functioning” scores reported in Stewart 
et al. [33] in order to obtain a single multiple 
myeloma-specific level of ability (69.28).
The survival curves presented in Figure 2 
are taken from Jakubowiak et al. [34], where 
overall survival data from the ASPIRE trial 
have been extrapolated beyond the duration 
of the trial, by fitting a Weibull parametric 
distribution to real-world observational data 
from the US SEER registry.
Finally, gender-specific prevalence data of 
multiple myeloma in Italy were taken from 
the Italian Association of Cancer Registries 
(AIRTUM) [35].
Given these survival, demographic and 
health-related data, the model, applying the 
half-cycle correction, estimates treatment-
specific Societal costs of lost production and 
informal care (Table VII).
These results can be better explained with the 
support of the treatment-specific survival cur-
ves. Thanks to KRd, patients are expected to 
live longer: this implies less production lost 
for society and therefore a lower incremen-
tal burden for premature death per patients 
– in particular a saving of 22.94% with re-
spect to Rd. However, this production is not 
completely restored for society because of 
the health-impairment of these individuals: 
these patients will not produce as their cor-
responding age- and gender-counterparts due 
to their reduced ability. Furthermore, because 
of their condition, they will need someone ta-
king care of them.
From the point of view of society this means 
that those savings are partially offset by the 
costs related with reduced ability the society 
has to bear: reduced productivity and need 
for informal care.
Being premature death the foremost cost item 
– accounting for more of 50% of societal 
costs in both treatments – the overall effect 
is that KRd implies an absolute saving per 
patient of € 13,075, equal to more than 7% 
savings.
dIscussIon
Despite their often profound impact, both 
productivity costs and informal care are 
recurrently excluded from economic eva-
luations of healthcare interventions. This 
neglecting may be related to the lack of gui-
dance and standardization in their measure-
ment and valuation.
estimated outcomes
Costs (€/pts)
KRd Rd KRd – Rd
Cost of premature death 87,813 113,959 - 26,146
Lost paid productivity for reduced ability 19,397 17,406 1,991
Lost unpaid productivity for reduced ability 22,859 17,217 5,642
Informal care for reduced ability 21,913 16,474 5,439
total 151,982 165,056 - 13,075
table VII. Example of model outcomes for the two treatment from the ASPIRE trial
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amount to 1.58% of the GDP of Italy in 2015, 
which is in line with the result for Spain.
There is also a heated debate in literature 
regarding the economic value of informal 
caregiving [41-44]. For instance in Oliva-
Moreno et al. [43] the total number of hours 
of informal care provided by main caregivers 
in Spain in 2008 was estimated at 4,193 mil-
lion, while monetary valuation ranged from 
€ 32,164 million to € 53,299 million using 
the proxy good method. Compared with the 
national GDP for 2008 the total value of in-
formal cares ranged from 2.96% to 4.90% of 
the national GDP.
Once again we did not have access to the 
same detailed data and therefore we were not 
able to replicate the same methodology. No-
netheless, when we estimated the economic 
value of informal caregiving in Italy in 2015, 
starting from demographic data and TUS, the 
estimated total numbers of hours of informal 
care provided in Italy in 2015 was 7,954 mil-
lion whose monetary evaluation amount to € 
77,713 million that represents the 4.73% of 
the Italian GDP in 2015.
conclusIons
Including costs of lost production and infor-
mal care in economic evaluations of healthca-
re interventions poses important methodolo-
gical questions. These are often excluded 
from economic evaluations. Partly, this may 
be explained by the lack of a standardized 
methodology. Inclusion of productivity loss 
and informal care is important to accurately 
inform decision makers about the costs and 
potential savings of healthcare interventions. 
It is recommended, for evaluations conducted 
from the Societal perspective to not only in-
clude productivity loss related to paid work, 
but also that related to unpaid activities and 
informal care.
We developed a standardized model able to 
estimate the monetary value of the Societal 
burden for lost production and informal care 
of a population of known demographic com-
position, survival curve and ability status. 
This result will be useful for health economic 
analyses conducted from the perspective of 
the Italian society.
We encourage the inclusion of these costs in 
economic evaluations to allow decision ma-
kers to be fully informed about the costs and 
consequences of their decisions on healthcare 
interventions.
For such reasons of convenience, uniformity 
and ease of use, the model relies on the data 
from the last available Italian TUS and from 
national health norms to define age- and gen-
der-specific benchmarks. Then, it only needs 
survival, demographic and functionality data 
in order to estimate disease- and treatment-
specific estimates of lost production and in-
formal care.
For what concerns HRQoL data, the model 
estimates the percentage difference from the 
population benchmark. In order to define 
age- and gender-specific population norms, 
for both production and self-care, we used 
the raw data of two - respectively “self-care” 
and “usual activities” - of the five domains of 
the EQ-5D as presented in Szende et al. [25].
Rather than relying on the single utility in-
dex as defined by EQ-5D and consequently 
taking into consideration the change in utility 
brought about by the disease/treatment, we 
decided to focus solely on the reduced ability 
to perform daily activities.
We believe that for estimating indirect costs 
and informal care, changes in physical im-
pairment suit better than changes in utility, 
being this a wide concept, encompassing 
many aspects.
Another study involving estimates of the 
overall cost of disease and health problems 
has been performed in Spain [38]. In spite of 
methodological differences, our model and 
this exhibit common patterns with respect to 
losses due to premature mortality.
We did not have access to the same detailed 
data and therefore we were not able to repli-
cate these results for Italy. We estimated the 
loss of paid production caused by premature 
death in Italy in 2015, starting from the num-
ber of deaths and from the model estimates of 
the present value of future productivity.
In Spain in 2005, there were a total of 387,355 
deaths and the loss of paid production caused 
by premature deaths has been estimated at € 
9,136 million. In Italy in 2015, there were a 
total of 647,571 deaths [39] and the model 
estimate a € 26,998 million loss of paid pro-
duction caused by premature deaths.
The Gross Domestic Product (GDP) of Spain 
for 2005 amounted to € 908,792 million. 
This means that paid production losses due 
to premature death were estimated to a figure 
equivalent to 1.01% of the GDP of Spain in 
2005. The GDP of Italy for 2015 amounted to 
€ 1,642,443 million [40] and therefore paid 
production losses due to premature death 
13Farmeconomia. Health economics and therapeutic pathways 2017; 18(1) © SEEd All rights reserved
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